FIRSTEC (A010820) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
22 Mar, 2026Executive summary
Revenue for FY2025 increased by 42.2% year-over-year to ₩294.8 billion, with operating income up 145.2% to ₩10.7 billion and net income up 34.9% to ₩14.7 billion.
Total assets grew 15.0% to ₩403.1 billion, and equity rose 29.5% to ₩82.5 billion, while liabilities increased 11.8% to ₩320.6 billion.
The company operates in the defense industry, focusing on weapons and security products, with 64% of sales concentrated among two major customers.
The audit opinion for FY2025 was unqualified, with no significant issues noted.
Financial highlights
Gross profit margin improved to 7.7% (₩22.8 billion gross profit on ₩294.8 billion sales).
Cash and cash equivalents at year-end were ₩50.0 billion, down from ₩94.4 billion, mainly due to negative operating and investing cash flows.
No outstanding borrowings at year-end; the company maintains a strong cash position.
R&D expenses increased to ₩1.04 billion, representing 0.35% of sales.
Outlook and guidance
Management expects continued uncertainty in 2026 due to global monetary tightening and economic challenges.
Focus remains on cost control, R&D, and strengthening competitiveness to withstand market volatility.
Latest events from FIRSTEC
- Q3 2025 saw ₩186.4B sales, ₩6.68B net income, and continued R&D-driven growth.A010820
Q3 202523 Nov 2025 - Q1 2025 revenue reached ₩53.6B with net income of ₩2.19B, driven by defense contracts.A010820
Q1 202525 Aug 2025 - Revenue and profit fell, but cash and assets rose as R&D and market expansion continued.A010820
Q3 202425 Aug 2025 - Revenue fell but net income turned positive; focus remains on R&D and future defense growth.A010820
Q2 202525 Aug 2025 - H1 2024 saw higher revenue and net income, with robust defense sales and increased cash reserves.A010820
Q2 202425 Aug 2025 - Revenue and net income surged, but leverage increased; 2025 outlook remains cautious.A010820
Q4 202425 Aug 2025